Cytek BioSciences Inc (NASDAQ:CTKB) price on Friday, April 11, rose 5.40% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $3.71.
A look at the stock’s price movement, the close in the last trading session was $3.52, moving within a range at $3.49 and $3.72. The beta value (5-Year monthly) was 1.413. Turning to its 52-week performance, $7.63 and $3.27 were the 52-week high and 52-week low respectively. Overall, CTKB moved -10.39% over the past month.
Cytek BioSciences Inc’s market cap currently stands at around $475.24 million, with investors looking forward to this quarter’s earnings report slated for on 2025-Feb-26.
Analysts have a consensus estimate of 43.3M for the company’s revenue for the quarter, with a low and high estimate of 42.5M and 44.73M respectively. The average forecast suggests down to a -3.47% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 206.09M, representing a 2.81% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that CTKB is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
4 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 1 analyst(s) rate the stock as a Hold, 3 recommend CTKB as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
CTKB’s current price about -6.00% and -18.04% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 39.99, while 7-day volatility ratio is 11.42% and 6.29% in the 30-day chart. Further, Cytek BioSciences Inc (CTKB) has a beta value of 1.42, and an average true range (ATR) of 0.27. Analysts have given the company’s stock an average 52-week price target of $6.625, forecast between a low of $5.25 and high of $8. Looking at the price targets, the low is -41.51% off current price level while to achieve the yearly target high, price needs to move -115.63%. Nonetheless, investors will most likely welcome a -78.57% jump to $6.625 which is the analysts’ median price.
If we refocus on Cytek BioSciences Inc (NASDAQ:CTKB), historical trading data shows that trading volumes averaged 0.94 over the past 10 days and 896.11K over the past 3 months. The company’s latest data on shares outstanding shows there are 129.21 million shares.
The 9.37% of Cytek BioSciences Inc’s shares are in the hands of company insiders while institutional holders own 60.11% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 3.81 million on 2025-03-14, giving us a short ratio of 5.13. The data shows that as of 2025-03-14 short interest in Cytek BioSciences Inc (CTKB) stood at 383.99998 of shares outstanding, with shares short rising to 3.46 million registered in 2025-02-14. Current price change has pushed the stock -42.84% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the CTKB stock continues to rise going into the next quarter.
